Xconomy: Agenda: What’s Hot in Cancer Immunotherapy 2017


		AGENDA
		.
	12:30 – 1:30	Registration & Networking
	1:30 – 1:40	Welcome and Opening Remarks Phil Greenberg, Head of the Program in Immunology and member of the Clinical Research Division, Fred Hutch; Professor of Medicine/Oncology and of Immunology, University of Washington Jim Edwards, Publisher, Xconomy
	1:40 – 2:10	Can CAR-T Be Tamed? Hans Bishop, CEO, Juno Therapeutics Richard Maziarz, Medical Director, Adult Blood and Marrow Stem Cell Transplant Program, Oregon Health and Science University Alex Lash, National Biotechnology Editor, Xconomy (moderator)
	2:10 – 2:40	Chasing Cancer Vaccines Andrew Allen, CEO, Gritstone Oncology Jay Venkatesan, President, Alpine Immune Sciences Alex Lash, National Biotechnology Editor, Xconomy (moderator)
	2:40 – 3:10	Teaming Up On Immunotherapy’s Frontier Jill O’Donnell-Tormey, CEO, Cancer Research Institute Ilya Shmulevich, Professor, Institute for Systems Biology Michael Kalos, Chief Scientific Officer, Cancer Immunobiology, Eli Lilly and Company Andrew Albertson, Partner, Fenwick & West (moderator)
	3:10 – 3:40	Networking Break
	3:40– 4:05	Kids, Cancer Care, and Lessons Learned Michael Jensen, MD, Director, Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute
	4:05 – 4:35	Deciphering The Immune System Brad Gray, CEO, NanoString Technologies Chad Robins, President & CEO, Adaptive Biotechnologies Alex Lash, National Biotechnology Editor, Xconomy (moderator)
	4:35 – 5:05	T Cell Treatments Under The Radar Maria Fardis, CEO, Lion Biotechnologies Sylvia Lee, Assistant Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
	5:05 – 5:30	How Lung Cancer Became Immunotherapy’s Biggest Success Renato Martins, Medical Director, Thoracic/Head and Neck Oncology, University of Washington School of Medicine
	5:30 – 6:30	Networking Reception

*Schedule is subject to change.

Register here.